Successful imatinib therapy for neuroendocrine carcinoma with activating KIT mutation: A case study

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 12, Issue 6, 2014, Pages 847-852

  Perkins, James ^a   Boland, Patrick ^b   Cohen, Steven J ^a   Olszanski, Anthony J ^a   Zhou, Yan ^a   Engstrom, Paul ^a   Astsaturov, Igor ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; CHROMOGRANIN B; CISPLATIN; ETOPOSIDE; FLUOROURACIL; GLYCOPROTEIN; IMATINIB; KINESIN 11 INHIBITOR; KINESIN INHIBITOR; MESSENGER RNA; STEM CELL FACTOR; STREPTOZOCIN; TRYPTOPHAN HYDROXYLASE; TUMOR MARKER; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; KIF11 PROTEIN, HUMAN; KINESIN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

ADULT; ANTINEOPLASTIC ACTIVITY; APPETITE; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CASE STUDY; COLON ADENOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER MODEL; COUGHING; DISEASE EXACERBATION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EXON; FINE NEEDLE ASPIRATION BIOPSY; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HEPATOMEGALY; HUMAN; INHALATION; LABORATORY TEST; LIVER BIOPSY; LIVER METASTASIS; LIVER SIZE; MALE; MIDDLE AGED; MITOSIS; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; PAIN ASSESSMENT; PALPATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHYSICAL EXAMINATION; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; UPPER ABDOMINAL PAIN; WEIGHT GAIN; ANTAGONISTS AND INHIBITORS; CARCINOMA, NEUROENDOCRINE; DRUG RESISTANCE; GASTROINTESTINAL STROMAL TUMORS; GENETICS; PATHOLOGY; SIGNAL TRANSDUCTION;

BENZAMIDES; CARCINOMA, NEUROENDOCRINE; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HUMANS; KINESIN; MALE; MIDDLE AGED; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 84902505841     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0079     Document Type: Article

References (22)

1. Bümming P, Nilsson O, Ahlman H, et al. Gastrointestinal stromal tumors regularly express synaptic vesicle proteins: evidence of a neuroendocrine phenotype. Endocr Relat Cancer 2007;14:853-863. (Pubitemid 350074073)
2. Grande E, Capdevila J, Barriuso J, et al. Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist? Cancer Metastasis Rev 2012;31:47-53.
3. Samaras VD, Foukas PG, Triantafyllou K, et al. Synchronous well differentiated neuroendocrine tumour and gastrointestinal stromal tumour of the stomach: a case report. BMC Gastroenterol 2011;11:27.
4. Engstrom PF, Lavin PT, Moertel CG, et al. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 1984;2:1255-1259. (Pubitemid 15202700)
5. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
6. Ashfaq R. Molecular profiling for personalized cancer care. Clin Exp Metastasis 2012;29:653-655.
7. Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-932. (Pubitemid 30618049)
8. Wadt K, Choi J, Chung JY, et al. A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma. Pigment Cell Melanoma Res 2012;25:815-818.
9. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072.
10. Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomidebased therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009;15:338-345.
11. Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999;81:1351-1355.
12. Sarli V, Giannis A. Targeting the kinesin spindle protein: basic principles and clinical implications. Clin Cancer Res 2008;14:7583-7587.
13. Ding S, Nishizawa K, Kobayashi T, et al. A potent chemotherapeutic strategy for bladder cancer: (S)-methoxy-trityl-L-cystein, a novel Eg5 inhibitor. J Urol 2010;184:1175- 1181.
14. Yao JC, Zhang JX, Rashid A, et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 2007;13:234-240. (Pubitemid 46121874)
15. Lankat-Buttgereit B, Horsch D, Barth P, et al. Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth. Digestion 2005;71:131-140. (Pubitemid 40910932)
16. Min KW, Leabu M. Interstitial cells of Cajal (ICC) and gastrointestinal stromal tumor (GIST): facts, speculations, and myths. J Cell Mol Med 2006;10:995-1013.
17. Huizinga JD, Thuneberg L, Kluppel M, et al. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 1995;373:347-349.
18. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580. (Pubitemid 28067289)
19. Lin YL, Wei CK, Chiang JK, et al. Concomitant gastric carcinoid and gastrointestinal stromal tumors: a case report. World J Gastroenterol 2008;14:6100-6103.
20. Maiorana A, Fante R, Maria Cesinaro A, et al. Synchronous occurrence of epithelial and stromal tumors in the stomach: a report of 6 cases. Arch Pathol Lab Med 2000;124:682-686. (Pubitemid 30321868)
21. Lauwers GY, Erlandson RA, Casper ES, et al. Gastrointestinal autonomic nerve tumors. A clinicopathological, immunohistochemical, and ultrastructural study of 12 cases. Am J Surg Pathol 1993;17:887-897. (Pubitemid 23245921)
22. Miettinen M, Makhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006;30:477-489. (Pubitemid 43740149)